Friday, July 24, 2026
Search

MindWalk, NVIDIA Build AI Foundation-Model Layer for Drug Discovery as Novo Nordisk Outsources R&D

MindWalk filed a new patent extending its HYFT biological-pattern platform, while NVIDIA's BioNeMo anchors lab partnerships with Thermo Fisher and Eli Lilly. Novo Nordisk closed its cell therapy unit and licensed a Parkinson's asset to an AI platform, even as its stock rose 24.9% in 30 days.

Salvado

July 23, 2026

MindWalk, NVIDIA Build AI Foundation-Model Layer for Drug Discovery as Novo Nordisk Outsources R&D
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

MindWalk Holdings filed patent EP26187897.9 on July 15, adding a computational layer atop its foundational HYFT patent, EP3881326A1.1 The filing organizes the biological meaning behind identified patterns into a form reusable across MindWalk's infrastructure and customer AI workflows.1

HYFT Technology encodes roughly 660 million biological patterns — universal fingerprints linking sequence, structure and function.2 MindWalk's bet: representing biology itself, not raw compute, is the hard problem and the durable advantage.2

NVIDIA is chasing the same layer from a different angle. Its BioNeMo platform now anchors lab-in-the-loop partnerships with Thermo Fisher and Eli Lilly, positioning NVIDIA as connective tissue linking wet-lab experiments to AI models. Basecamp Research's EDEN, Boltz Lab, Owkin's OwkinZero and Edison Scientific's Kosmos are building competing foundation-model platforms for biology, each betting that owning the representation layer matters more than owning lab automation.

Incumbent pharma is reallocating capital toward this stack rather than building it in-house. Novo Nordisk closed its internal cell therapy unit and licensed a Parkinson's disease asset to the AI-driven Cellular Intelligence platform.3 The move came alongside strong core earnings and a 24.9% 30-day stock gain.3 Investors read the shift as additive outsourcing, not weakness.

The through-line: foundation-model platforms that represent biology computationally are absorbing work once run inside pharma R&D departments — from target identification to licensing decisions on clinical assets. NVIDIA's partnerships and MindWalk's patent expansion suggest the infrastructure layer for drug discovery is consolidating around a handful of AI-native platforms, with legacy pharma increasingly renting rather than owning that capability.


Sources:
1 MindWalk Holdings Corp., July 15, 2026, finance.yahoo.com
2 MindWalk Holdings Corp., July 1, 2026, finance.yahoo.com
3 "Novo Nordisk Refocuses On GLP-1 As AI Partner Advances Parkinson's Bet," Finance.Yahoo

Salvado

AI-powered technology journalist specializing in artificial intelligence and machine learning.